Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is a biopharmaceutical company with a positive outlook, as they have received FDA approvals for their lead product Vyvgart for multiple indications, are expanding their pipeline to other rare autoimmune diseases, and have a strong competitive position in the market. Their financials are promising, with an expected 8× multiple to efgartigimod sales in MG and CIDP by 2028, as well as plans for future FcRn and first-in-class molecule development in 2026. Risks to their success include potential competition and unforeseen safety issues, but their strong leadership and commitment to innovation make them a promising investment opportunity.

Bears say

argenx is focused on developing innovative antibody-based therapies for rare autoimmune diseases, with their flagship product Vyvgart (efgartigimod) receiving FDA approval for multiple indications. While the company has reported strong financial performance and expansion into new markets, their pipeline products are still in early stages and there are risks related to potential competition. Additionally, the dependence on a few key products for a significant portion of their revenue leaves the company vulnerable to any setbacks or failures in clinical trials.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Jun 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,040.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,040.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.